Toronto Dominion Bank Acquires 3,470 Shares of Haleon plc (NYSE:HLN)

Toronto Dominion Bank grew its stake in Haleon plc (NYSE:HLN) by 3,470.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,570 shares of the company’s stock after buying an additional 3,470 shares during the quarter. Toronto Dominion Bank’s holdings in Haleon were worth $38,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in HLN. Y Intercept Hong Kong Ltd acquired a new stake in shares of Haleon in the 3rd quarter valued at about $600,000. EP Wealth Advisors LLC raised its position in Haleon by 34.2% in the 3rd quarter. EP Wealth Advisors LLC now owns 26,982 shares of the company’s stock valued at $285,000 after buying an additional 6,872 shares during the last quarter. Insigneo Advisory Services LLC lifted its stake in Haleon by 6.6% in the 3rd quarter. Insigneo Advisory Services LLC now owns 35,961 shares of the company’s stock valued at $380,000 after acquiring an additional 2,235 shares in the last quarter. Jane Street Group LLC boosted its position in Haleon by 1,689.4% during the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock worth $2,803,000 after acquiring an additional 250,169 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new position in shares of Haleon during the 3rd quarter worth approximately $137,000. 6.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HLN. Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.95.

Haleon Trading Down 0.4 %

Shares of Haleon stock opened at $9.72 on Tuesday. The stock has a market cap of $44.00 billion, a P/E ratio of 28.59, a P/E/G ratio of 2.95 and a beta of 0.28. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The business’s 50 day moving average is $9.74 and its 200-day moving average is $9.54.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.